Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 2750 | 19.21 |
09:36 ET | 162 | 19.18 |
09:38 ET | 100 | 19.2 |
09:41 ET | 649 | 19.06 |
09:43 ET | 1100 | 19.055 |
09:48 ET | 200 | 19.08 |
09:52 ET | 600 | 19.17 |
09:56 ET | 1312 | 19.095 |
09:57 ET | 100 | 19.095 |
10:06 ET | 1000 | 19.08 |
10:08 ET | 500 | 19.1 |
10:10 ET | 100 | 19.1 |
10:12 ET | 1121 | 19.06 |
10:14 ET | 100 | 19.08 |
10:15 ET | 100 | 19.09 |
10:17 ET | 400 | 19.09 |
10:21 ET | 500 | 19.17 |
10:26 ET | 300 | 19.16 |
10:28 ET | 617 | 19.08 |
10:30 ET | 200 | 19.05 |
10:32 ET | 200 | 19.08 |
10:35 ET | 100 | 19.09 |
10:37 ET | 1113 | 19.02 |
10:39 ET | 100 | 19.05 |
10:44 ET | 400 | 19.06 |
10:46 ET | 412 | 19.05 |
10:48 ET | 200 | 19.05 |
10:55 ET | 134 | 19.04 |
10:57 ET | 10390 | 19.06 |
11:00 ET | 200 | 19.05 |
11:02 ET | 252 | 19.05 |
11:04 ET | 100 | 19.05 |
11:06 ET | 200 | 19.05 |
11:08 ET | 200 | 19.03 |
11:09 ET | 298 | 19.045 |
11:13 ET | 800 | 19.08 |
11:15 ET | 200 | 19.12 |
11:22 ET | 1392 | 19.1 |
11:29 ET | 300 | 19.08 |
11:38 ET | 100 | 19.04 |
11:44 ET | 518 | 19.03 |
11:49 ET | 600 | 19.025 |
11:51 ET | 100 | 19.01 |
11:54 ET | 800 | 19.03 |
12:00 ET | 600 | 19.02 |
12:02 ET | 100 | 18.99 |
12:05 ET | 300 | 18.99 |
12:07 ET | 700 | 18.93 |
12:12 ET | 200 | 18.92 |
12:14 ET | 403 | 18.945 |
12:16 ET | 300 | 18.92 |
12:18 ET | 2000 | 18.85 |
12:20 ET | 2793 | 18.84 |
12:21 ET | 212 | 18.82 |
12:23 ET | 6414 | 18.8 |
12:30 ET | 212 | 18.78 |
12:34 ET | 1032 | 18.76 |
12:39 ET | 158 | 18.765 |
12:45 ET | 700 | 18.75 |
12:48 ET | 500 | 18.78 |
12:50 ET | 407 | 18.78 |
12:56 ET | 300 | 18.79 |
12:57 ET | 500 | 18.78 |
12:59 ET | 800 | 18.82 |
01:01 ET | 1280 | 18.82 |
01:03 ET | 118 | 18.81 |
01:06 ET | 476 | 18.8 |
01:14 ET | 726 | 18.815 |
01:15 ET | 175 | 18.8397 |
01:17 ET | 1200 | 18.82 |
01:21 ET | 100 | 18.825 |
01:24 ET | 14668 | 18.89 |
01:26 ET | 106 | 18.87 |
01:28 ET | 100 | 18.85 |
01:30 ET | 200 | 18.82 |
01:32 ET | 100 | 18.845 |
01:33 ET | 200 | 18.855 |
01:35 ET | 200 | 18.84 |
01:37 ET | 1600 | 18.855 |
01:42 ET | 300 | 18.87 |
01:44 ET | 1063 | 18.85 |
01:48 ET | 100 | 18.83 |
01:50 ET | 1000 | 18.83 |
01:53 ET | 400 | 18.82 |
01:57 ET | 200 | 18.81 |
02:02 ET | 2764 | 18.84 |
02:06 ET | 900 | 18.84 |
02:11 ET | 1000 | 18.9041 |
02:13 ET | 1112 | 18.89 |
02:15 ET | 200 | 18.9 |
02:20 ET | 693 | 18.88 |
02:26 ET | 400 | 18.87 |
02:27 ET | 700 | 18.9 |
02:31 ET | 2023 | 18.87 |
02:36 ET | 501 | 18.86 |
02:42 ET | 600 | 18.88 |
02:45 ET | 500 | 18.88 |
02:51 ET | 200 | 18.89 |
02:56 ET | 600 | 18.9 |
02:58 ET | 2349 | 18.875 |
03:00 ET | 504 | 18.86 |
03:05 ET | 100 | 18.88 |
03:07 ET | 1200 | 18.92 |
03:09 ET | 100 | 18.94 |
03:12 ET | 300 | 18.93 |
03:14 ET | 618 | 18.95 |
03:16 ET | 600 | 18.95 |
03:20 ET | 600 | 18.97 |
03:21 ET | 1155 | 18.96 |
03:25 ET | 500 | 19 |
03:27 ET | 1083 | 18.96 |
03:30 ET | 200 | 18.96 |
03:32 ET | 200 | 18.98 |
03:34 ET | 700 | 19 |
03:36 ET | 1513 | 19.01 |
03:38 ET | 1075 | 19.01 |
03:41 ET | 400 | 19.01 |
03:43 ET | 809 | 19.02 |
03:45 ET | 700 | 19.02 |
03:48 ET | 1309 | 19.035 |
03:50 ET | 451 | 19.04 |
03:52 ET | 1454 | 19.03 |
03:54 ET | 1549 | 19.02 |
03:56 ET | 527 | 19.01 |
03:57 ET | 3529 | 19 |
03:59 ET | 9880 | 19.04 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 223.5x | --- |
Ginkgo Bioworks Holdings Inc | 1.4B | -1.4x | --- |
Dynavax Technologies Corp | 1.5B | 230.2x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -5.8x | --- |
Zai Lab Ltd | 1.8B | -5.3x | --- |
MannKind Corp | 1.3B | 197.6x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 223.5x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | 124.4x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.